News articles about AtriCure (NASDAQ:ATRC) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AtriCure earned a news impact score of 0.24 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.6021222413004 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Several brokerages have recently issued reports on ATRC. Canaccord Genuity reduced their price target on AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Needham & Company LLC reduced their price target on AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. TheStreet lowered AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. ValuEngine lowered AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $24.00 price target on shares of AtriCure in a report on Sunday, December 10th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $24.33.

Shares of AtriCure (ATRC) traded up $0.26 during trading on Friday, hitting $15.31. The stock had a trading volume of 249,105 shares, compared to its average volume of 153,919. The firm has a market cap of $527.80, a price-to-earnings ratio of -15.01 and a beta of 0.39. The company has a current ratio of 2.28, a quick ratio of 1.65 and a debt-to-equity ratio of 0.20. AtriCure has a fifty-two week low of $14.88 and a fifty-two week high of $25.18.

In related news, CFO M. Andrew Wade sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “AtriCure (ATRC) Earning Somewhat Favorable Press Coverage, Analysis Finds” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2018/02/11/atricure-atrc-earning-somewhat-favorable-press-coverage-analysis-finds.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.